Structural analysis has revealed for the first time how a key messenger in the body’s chemical communication system hooks up with one of the proteins that delivers it to sites of action in the body. Using X-ray crystallography, scientists from Imperial College London and the University of Hawaii have identified the location of four binding sites on human serum albumin (HSA), the principal protein in blood plasma, to which the chemical messenger thyroxine attaches. From Imperial College of Science, Technology and Medicine :Study of thyroxine transporter molecule shows how key hormone hitches a lift round body
Findings may aid the development of drugs to treat thyroid disorders
Structural analysis has revealed for the first time how a key messenger in the body’s chemical communication system hooks up with one of the proteins that delivers it to sites of action in the body.
Using X-ray crystallography, scientists from Imperial College London and the University of Hawaii have identified the location of four binding sites on human serum albumin (HSA), the principal protein in blood plasma, to which the chemical messenger thyroxine attaches.
Thyroxine is the primary hormone released from the thyroid gland, and acts on nearly every cell in the body affecting important mechanisms that control, weight, energy level, memory and heart rate.
While HSA is not the major transporter of thyroxine, its quick and direct action provides the most ready supply of the hormone for use around the body.
The findings, which are published online this week in the Proceedings of the National Academy of Science, help to explain how thyroxine regulates metabolic processes and normal physical development, and may aid the development of drugs to treat thyroid disorders.
The structural information also sheds light on the molecular basis of a rare condition, familial dysalbuminemic hyperthyroxemia (FDH), which is caused by mutations in HSA. This harmless genetic disorder is often misdiagnosed as an overactive thyroid gland and treated inappropriately.
Dr Stephen Curry of Imperial’s Department of Biological Sciences and senior author of the study said:
“Our study provides a more complete understanding of how thyroxine binds to HSA. Previously the number and location of binding sites on HSA was not clear. This structural information can now be used to help design synthetic forms of thyroxine to treat thyroid disorders. It will allow more detailed analysis of how the two molecules interact in the body, which can be used to make more effective candidate drugs.”
HSA is the most abundant protein in the circulatory system. Its principal function is to transport fatty acids, but it is also one of three proteins that delivers thyroxine.
Levels of thyroxine circulating in the body are used as a biochemical indicator to help gauge how active the thyroid gland is. The researchers sought a better understanding of how the hormone binds to the proteins that transport it in order to improve diagnosis of the various thyroid disorders.
Together with colleagues in Hawaii, the Imperial team, who are the main academic research group in the world working on albumin structures, examined the crystallised structure of HSA bound to thyroxine under three different conditions: in the presence or absence of fatty acids and using mutant forms of HSA.
“The shape of the HSA-thyroxine complex alters dramatically when fatty acids bind to the protein,” explained Dr Curry. “The main difference is that when fatty acids are present, their binding creates a new binding site.
“This is an unprecedented example of the complex interplay between the binding of fatty acids and thyroxine to the protein. Although fatty acids and thyroxine compete with one another to bind to several sites on the protein, there is also an element of cooperation through the creation of an additional binding site for the hormone. “The interaction between the FDH causing mutant forms of HSA and thyroxine increases the binding affinity between the two molecules 10 to 15 fold. People with this condition present with normal levels of thyroxine that is not bound to transporter proteins but when the total level of thyroxine is looked at it’s much higher. Our research will allow a more accurate diagnosis of this condition in the future.”
The research was supported by the American Heart Foundation, Hawaii Affiliate and the Biotechnology and Biological Sciences Research Council (UK).
For further information, please contact:
Judith H Moore
Imperial College London Press Office
Notes to Editors
Journal: Proceedings of the National Academy of Science http://www.pnas.org/cgi/reprint/1137188100v1.pdf
Tile: “Structural basis of albumin thyroxine interactions and familial dysalbuminemic hyerthyroxinemia”
Authors: Isabelle Petitpas (1), Charles E Petersen (2), Chung-Eun Ha (2), Ananyo A Bhattacharya (1), Patricia A Zunszain (1), Jamie Ghuman (1), Nadhipuram V Bhagavan and Stephen Curry (1)
(1) Biophysics section, Department of Biological Sciences, Imperial College London, SW7 2BW
(2) Department of Biochemistry and Biophysics, John A Burns School of Medicine, university of Hawaii, Honolulu, HI 96822
About Imperial College London
Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (10,000) and staff (5,000) of the highest international quality.
Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions, which enhance the quality of life and the environment – underpinned by a dynamic enterprise culture.